| Nov 12 |
QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations
|
| Nov 7 |
Quoin Pharmaceuticals GAAP EPS of -$0.47 misses by $0.01
|
| Nov 7 |
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
|
| Nov 5 |
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
|
| Oct 31 |
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
|
| Oct 22 |
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
|
| Oct 17 |
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
|
| Sep 9 |
Quoin Pharmaceuticals announces insider share purchases
|
| Sep 9 |
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
|
| Aug 22 |
QNRX: Assessing QRX003 For Multiple Conditions; Opening International Netherton Syndrome Clinical Sites
|
